Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sutro Biopharma Inc

0.7248
+0.172531.23%
Post-market: 0.74990.0251+3.46%19:20 EDT
Volume:5.41M
Turnover:3.67M
Market Cap:60.72M
PE:-0.24
High:0.7789
Open:0.5600
Low:0.5600
Close:0.5523
Loading ...

Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

TipRanks
·
18 Mar

Sutro Biopharma Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
17 Mar

Sutro Biopharma, Inc. : H.c. Wainwright Cuts Target Price to $2 From $12

THOMSON REUTERS
·
17 Mar

Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform

MT Newswires Live
·
17 Mar

Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating

MT Newswires Live
·
17 Mar

Sutro Biopharma Inc. : Deutsche Bank Cuts Target Price to $5 From $10

THOMSON REUTERS
·
17 Mar

Sutro Biopharma presents expanded data from REFRalphaME-01 trial

TIPRANKS
·
17 Mar

Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
16 Mar

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

TipRanks
·
15 Mar

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ...

GuruFocus.com
·
15 Mar

Sutro Biopharma Cut to Market Perform From Market Outperform by Citizens Capital Markets

Dow Jones
·
14 Mar

Nasdaq Surges 1.5%; Ulta Beauty Posts Upbeat Results

Benzinga
·
14 Mar

Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8

MT Newswires Live
·
14 Mar

Sutro Biopharma Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $2 From $8

THOMSON REUTERS
·
14 Mar

Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs

GuruFocus.com
·
14 Mar

Truist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)

TIPRANKS
·
14 Mar

Sutro Biopharma Inc : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $2 From $8

THOMSON REUTERS
·
14 Mar

Sutro Biopharma Cut to Underperform From Buy by B of A Securities

Dow Jones
·
14 Mar

Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating

MT Newswires Live
·
14 Mar

Sutro Biopharma downgraded to Underperform from Buy at BofA

TIPRANKS
·
14 Mar